Personen

TOP 5 Publikationen:

1. Sartorius A, Demirakca T, Böhringer A, Clemm von Hohenberg C, Aksay SS, Bumb JM, Kranaster L, Nickl-Jockschat T, Grözinger M, Thomann PA, Wolf RC, Zwanzger P, Dannlowski U, Redlich R, Zavorotnyy M, Zöllner R, Methfessel I, Besse M, Zilles D, Ende G. Electroconvulsive therapy induced gray matter increase is not necessarily correlated with clinical data in depressed patients.Brain Stimul. 2019 12(2):335-343. Epub 2018 Dec 4.
2. Sartorius A, Beuschlein J, Remennik D, Pfeifer AM, Karl S, Bumb JM, Aksay SS, Kranaster L, Janke C. Empirical ratio of the combined use of S-ketamine and propofol in electroconvulsive therapy and its impact on seizure quality.Eur Arch Psychiatry Clin Neurosci. 2021 271(3):457-463. Epub 2021 Jul 22.
3. Kranaster L, Hoyer C, Aksay SS, Bumb JM, Müller N, Zill P, Schwarz MJ, Sartorius A. Markers of the innate immune system in the cerebrospinal fluid in patients with severe depression.Acta Psychiatr Scand. 2017 136(1):140-141. Epub 2017 May 13.
4. Hoyer C, Sartorius A, Aksay SS, Bumb JM, Janke C, Thiel M, Haffner D, Leifheit-Nestler M, Kranaster L. Electroconvulsive therapy enhances the anti-ageing hormone Klotho in the cerebrospinal fluid of geriatric patients with major depression.Eur Neuropsychopharmacol. 2018 28(3):428-435. Epub 2017 Dec 20.
5. Kranaster L, Badstübner J, Aksay SS, Bumb JM, Suliman R, Neumaier M, Sartorius A. Evaluation of Myocardial Damage After Electroconvulsive Therapy: Analyses of High-Sensitive Cardiac Troponin I and N-Terminal pro-B-type Natriuretic Peptide.Pharmacopsychiatry. 2019 52(2):92-93. Epub 2018 Jul 2.